Bisphosphonate Cancer Risk Divides FDA Officials Ahead Of Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will ask panel whether potential long-term risks of the osteoporosis drugs could be avoided through a "drug holiday."
You may also be interested in...
Bisphosphonates Facing Riskier Committee As FDA Adds Esophageal Cancer To Advisory Panel Agenda
FDA revises topics for September committee two weeks after announcing the meeting.
Bisphosphonates Might Get Limits On Treatment Duration Following Label Change
Accumulating data on femur fractures lead FDA to consider telling physicians to take patients off the drug at least temporarily when bone mineral density targets are reached.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.